Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) trials

Saranya Chumsri, Daniel J. Serie, Zhuo Li, Katherine L. Pogue-Geile, Aixa E. Soyano-Muller, Afshin Mashadi-Hossein, Sarah Warren, Yanyan Lou, Gerardo Colon-Otero, Keith L Knutson, Edith A. Perez, Alvaro Moreno Aspitia, E Aubrey Thompson

Research output: Contribution to journalArticle

Abstract

Purpose: Young age has been shown to be an independent 0.68; P < 0.001; and age > 40; HR, 0.42; 95% CI, 0.33–0.54; P < predictor of poor outcome in breast cancer. In HER2-positive 0.001). Among patients who received chemotherapy alone, breast cancer, the effects of aging remain largely unknown. younger age was associated with poor outcome in the hor-Experimental Design: A total of 4,547 patients were mone receptor–positive subset, but not the hormone recep-included [3,132 from North Central Cancer Treatment tor–negative subset, in both trials. Although there was no Group (NCCTG) N9831 and 1,415 from National Surgical association between sTILs and age, a small, but significant Adjuvant Breast and Bowel Project (NSABP) B-31]. Patho-increase in mTIL CD45 and some immune subset signatures logic stromal tumor-infiltrating lymphocyte (sTIL) and were observed. Among patients who received chemotherapy molecular tumor infiltrating lymphocyte (mTIL) signatures alone, patients over 40 years of age with lymphocyte-predom-were evaluated. inant breast cancer had excellent outcome, with 95% remain-Results: In NCCTG N9831, comparable benefit of trastu-ing recurrence free at 15 years. zumab was observed in all patients [age 40; HR, 0.43; 95% Conclusions: Among patients treated with trastuzumab, confidence interval (CI), 0.28–0.66; P < 0.001; and age > 40; there was no significant difference in outcome related to age. HR, 0.56; 95% CI, 0.45–0.69; P < 0.001]. Similar results were Our study suggests that trastuzumab can negate the poor observed in NSABP B-31 (age 40; HR, 0.45; 95% CI, 0.29–prognosis associated with young age.

Original languageEnglish (US)
Pages (from-to)4422-4430
Number of pages9
JournalClinical Cancer Research
Volume25
Issue number14
DOIs
StatePublished - Jan 1 2019

Fingerprint

Breast Neoplasms
adjuvant P40
B 31
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) trials. / Chumsri, Saranya; Serie, Daniel J.; Li, Zhuo; Pogue-Geile, Katherine L.; Soyano-Muller, Aixa E.; Mashadi-Hossein, Afshin; Warren, Sarah; Lou, Yanyan; Colon-Otero, Gerardo; Knutson, Keith L; Perez, Edith A.; Moreno Aspitia, Alvaro; Thompson, E Aubrey.

In: Clinical Cancer Research, Vol. 25, No. 14, 01.01.2019, p. 4422-4430.

Research output: Contribution to journalArticle

Chumsri, Saranya ; Serie, Daniel J. ; Li, Zhuo ; Pogue-Geile, Katherine L. ; Soyano-Muller, Aixa E. ; Mashadi-Hossein, Afshin ; Warren, Sarah ; Lou, Yanyan ; Colon-Otero, Gerardo ; Knutson, Keith L ; Perez, Edith A. ; Moreno Aspitia, Alvaro ; Thompson, E Aubrey. / Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) trials. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 14. pp. 4422-4430.
@article{1b418e4903784cfda5e7fd69522c67d1,
title = "Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) trials",
abstract = "Purpose: Young age has been shown to be an independent 0.68; P < 0.001; and age > 40; HR, 0.42; 95{\%} CI, 0.33–0.54; P < predictor of poor outcome in breast cancer. In HER2-positive 0.001). Among patients who received chemotherapy alone, breast cancer, the effects of aging remain largely unknown. younger age was associated with poor outcome in the hor-Experimental Design: A total of 4,547 patients were mone receptor–positive subset, but not the hormone recep-included [3,132 from North Central Cancer Treatment tor–negative subset, in both trials. Although there was no Group (NCCTG) N9831 and 1,415 from National Surgical association between sTILs and age, a small, but significant Adjuvant Breast and Bowel Project (NSABP) B-31]. Patho-increase in mTIL CD45 and some immune subset signatures logic stromal tumor-infiltrating lymphocyte (sTIL) and were observed. Among patients who received chemotherapy molecular tumor infiltrating lymphocyte (mTIL) signatures alone, patients over 40 years of age with lymphocyte-predom-were evaluated. inant breast cancer had excellent outcome, with 95{\%} remain-Results: In NCCTG N9831, comparable benefit of trastu-ing recurrence free at 15 years. zumab was observed in all patients [age 40; HR, 0.43; 95{\%} Conclusions: Among patients treated with trastuzumab, confidence interval (CI), 0.28–0.66; P < 0.001; and age > 40; there was no significant difference in outcome related to age. HR, 0.56; 95{\%} CI, 0.45–0.69; P < 0.001]. Similar results were Our study suggests that trastuzumab can negate the poor observed in NSABP B-31 (age 40; HR, 0.45; 95{\%} CI, 0.29–prognosis associated with young age.",
author = "Saranya Chumsri and Serie, {Daniel J.} and Zhuo Li and Pogue-Geile, {Katherine L.} and Soyano-Muller, {Aixa E.} and Afshin Mashadi-Hossein and Sarah Warren and Yanyan Lou and Gerardo Colon-Otero and Knutson, {Keith L} and Perez, {Edith A.} and {Moreno Aspitia}, Alvaro and Thompson, {E Aubrey}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-18-2206",
language = "English (US)",
volume = "25",
pages = "4422--4430",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) trials

AU - Chumsri, Saranya

AU - Serie, Daniel J.

AU - Li, Zhuo

AU - Pogue-Geile, Katherine L.

AU - Soyano-Muller, Aixa E.

AU - Mashadi-Hossein, Afshin

AU - Warren, Sarah

AU - Lou, Yanyan

AU - Colon-Otero, Gerardo

AU - Knutson, Keith L

AU - Perez, Edith A.

AU - Moreno Aspitia, Alvaro

AU - Thompson, E Aubrey

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Young age has been shown to be an independent 0.68; P < 0.001; and age > 40; HR, 0.42; 95% CI, 0.33–0.54; P < predictor of poor outcome in breast cancer. In HER2-positive 0.001). Among patients who received chemotherapy alone, breast cancer, the effects of aging remain largely unknown. younger age was associated with poor outcome in the hor-Experimental Design: A total of 4,547 patients were mone receptor–positive subset, but not the hormone recep-included [3,132 from North Central Cancer Treatment tor–negative subset, in both trials. Although there was no Group (NCCTG) N9831 and 1,415 from National Surgical association between sTILs and age, a small, but significant Adjuvant Breast and Bowel Project (NSABP) B-31]. Patho-increase in mTIL CD45 and some immune subset signatures logic stromal tumor-infiltrating lymphocyte (sTIL) and were observed. Among patients who received chemotherapy molecular tumor infiltrating lymphocyte (mTIL) signatures alone, patients over 40 years of age with lymphocyte-predom-were evaluated. inant breast cancer had excellent outcome, with 95% remain-Results: In NCCTG N9831, comparable benefit of trastu-ing recurrence free at 15 years. zumab was observed in all patients [age 40; HR, 0.43; 95% Conclusions: Among patients treated with trastuzumab, confidence interval (CI), 0.28–0.66; P < 0.001; and age > 40; there was no significant difference in outcome related to age. HR, 0.56; 95% CI, 0.45–0.69; P < 0.001]. Similar results were Our study suggests that trastuzumab can negate the poor observed in NSABP B-31 (age 40; HR, 0.45; 95% CI, 0.29–prognosis associated with young age.

AB - Purpose: Young age has been shown to be an independent 0.68; P < 0.001; and age > 40; HR, 0.42; 95% CI, 0.33–0.54; P < predictor of poor outcome in breast cancer. In HER2-positive 0.001). Among patients who received chemotherapy alone, breast cancer, the effects of aging remain largely unknown. younger age was associated with poor outcome in the hor-Experimental Design: A total of 4,547 patients were mone receptor–positive subset, but not the hormone recep-included [3,132 from North Central Cancer Treatment tor–negative subset, in both trials. Although there was no Group (NCCTG) N9831 and 1,415 from National Surgical association between sTILs and age, a small, but significant Adjuvant Breast and Bowel Project (NSABP) B-31]. Patho-increase in mTIL CD45 and some immune subset signatures logic stromal tumor-infiltrating lymphocyte (sTIL) and were observed. Among patients who received chemotherapy molecular tumor infiltrating lymphocyte (mTIL) signatures alone, patients over 40 years of age with lymphocyte-predom-were evaluated. inant breast cancer had excellent outcome, with 95% remain-Results: In NCCTG N9831, comparable benefit of trastu-ing recurrence free at 15 years. zumab was observed in all patients [age 40; HR, 0.43; 95% Conclusions: Among patients treated with trastuzumab, confidence interval (CI), 0.28–0.66; P < 0.001; and age > 40; there was no significant difference in outcome related to age. HR, 0.56; 95% CI, 0.45–0.69; P < 0.001]. Similar results were Our study suggests that trastuzumab can negate the poor observed in NSABP B-31 (age 40; HR, 0.45; 95% CI, 0.29–prognosis associated with young age.

UR - http://www.scopus.com/inward/record.url?scp=85069037741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069037741&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2206

DO - 10.1158/1078-0432.CCR-18-2206

M3 - Article

C2 - 30808774

AN - SCOPUS:85069037741

VL - 25

SP - 4422

EP - 4430

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -